<DOC>
	<DOCNO>NCT00874848</DOCNO>
	<brief_summary>The Phase 2 study describe protocol serve evaluate antitumor activity , safety pharmacokinetic profile Imprime PGG combine cetuximab concomitant paclitaxel carboplatin therapy patient previously untreated advanced NSCLC . Additionally , study provide guidance design definitive efficacy study Imprime PGG NSCLC patient .</brief_summary>
	<brief_title>Efficacy/Safety Imprime PGG With Cetuximab &amp; Paclitaxel/Carboplatin Therapy Pts With Untreated Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Has read , understood sign informed consent form ( ICF ) approve Independent Review Board/Ethics Committee ( IRB/EC ) 2 . Is ages 18 75 year old , inclusive 3 . Has histologically cytologically confirm stage IIIB ( malignant pericardial pleural effusion ) stage IV nonsmall cell lung cancer 4 . Has measurable disease , define least one tumor fulfill criterion target lesion accord RECIST 5 . Has ECOG performance status 0 1 6 . Has life expectancy &gt; 3 month 7 . Has adequate hematologic function evidence : ANC ≥ 1,500/μL PLT ≥ 100,000/μL HGB ≥ 9 g/dL obtain within 1 week prior first dose study medication ; 8 . Has adequate renal function evidence : Serum creatinine ≤ 1.5 X upper limit normal ( ULN ) reference lab Urine dipstick proteinuria &lt; 1+ ( i.e. , either 0 trace ) within 2 week Day 1 If urine dipstick ≥ 1+ , urine protein excretion must ≤ 500 mg 24 hour collection obtain within 1 week prior first dose study medication ; 9 . Has adequate hepatic function evidence : Serum total bilirubin ≤ 1.0 mg/dL AST ≤ 2.5X ULN reference lab ( ≤ 5X ULN subject know hepatic metastasis ) ALT ≤ 2.5X ULN reference lab ( ≤ 5X ULN subject know hepatic metastasis ) obtain within 1 week prior first dose study medication ; 10 . If woman childbearing potential fertile man ( partner ) , must agree use effective form contraception ( hormonal contraceptive , doublebarrier method abstinence ) study . 1 . Has receive prior systemic chemotherapy time lung cancer ; 2 . Has receive previous radiation therapy &gt; 30 % active bone marrow radiation therapy within 3 week Day 1 3 . Has know hypersensitivity baker 's yeast , active yeast infection 4 . Has previous exposure Betafectin® Imprime PGG 5 . Has active infection 6 . Presents follow medical diagnoses/conditions time screening : Central nervous system ( CNS ) metastases Uncontrolled hypertension ( &gt; 150/100 mmHg ) hypertension require &gt; two agent adequate control Peripheral neuropathy ≥ grade 2 cause Fever &gt; 38.5° C within 3 day prior screen Day 1 , initial dose Known HIV/AIDs , Hepatitis B , Hepatitis C , connective tissue autoimmune disease , clinical diagnosis , ongoing intercurrent illness physician 's opinion could interfere participation 7 . Has history follow medical diagnoses/conditions : Myocardial infarction unstable uncontrolled disease condition relate impacting cardiac function ( e.g. , unstable angina , congestive heart failure ) within previous 6 month Second malignancy within previous 5 year , basal cell carcinoma , cervical intraepithelial neoplasia curatively treated prostate cancer PSA &lt; 2.0 ng/mL 8 . Has know hypersensitivity cetuximab , murine protein , component cetuximab 9 . Has know sensitivity Cremophor EL 10 . Has previously receive treatment cetuximab 11 . If female , pregnant breastfeed 12 . Is receive concurrent investigational therapy receive investigational therapy within period 30 day prior first schedule day dose ( investigational therapy define treatment currently regulatoryauthorityapproved indication ) 13 . Has previously receive organ progenitor/stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Imprime PGG</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Cetuximab</keyword>
</DOC>